• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245353 1628 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-26 22:27:08 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-26 22:36 编辑
9 ^. }& x7 ^" @! l2 @2 @' ?  h5 n1 x" o6 Y! G  w
4月20日:美国华盛顿大学医学院Govindan等人报告一项多中心Ⅱ期临床研究称:对于化疗过的非亚裔晚期NSCLC患者,使用S-1单药的耐受性良好,而且疗效可与其他已批准的药物想媲美。该报告发表在2011年2月15日的《JThoracOncol》在线版上。* J( S0 x# I9 _& M0 r2 U8 r+ Q2 _& [
  S1是一种新型的口服氟脲嘧啶制剂,在日本NSCLC患者中已显示有一定疗效,且耐药性良好。研究人员从美国21个中心入组了57例晚期NSCLC患 者,都是只接受过一次化疗。对所有患者予S-1(30mg/m2,q12h,连续14天后休息7天)化疗,直至符合停药标准为止。主要的研究终点为客观缓 解率。
! x& G% H4 c; F9 }1 z# N  根据独立评估结果,研究结果如下:客观缓解率和疾病稳定率分别是7.1%和48.2%,疾病控制率为55.3%。无进展生存期2.9个月,中位总生存 7.3个月,1年的生存率为31.6%。各组织学亚型患者生存期没有明显的差异。患者对S-1的耐受性良好,最常见的因治疗引起的不良反应有恶心 (54%)和腹泻(49%)。
, v* @& Z' a5 [ 氟尿嘧啶类药物的疗效预测标志物的研究进展.pdf (876.72 KB, 下载次数: 156)

Phase_II_Trial_of_S_1_as_Second_Line_Therapy_in.20.pdf

370.92 KB, 下载次数: 126

个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 15:58:09 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-27 18:25 编辑
3 y" M  J* U, k# ^5 S. L
5 L7 P: D4 G9 u0 s今天上单药泰素帝。
7 N" k5 f9 y2 J# t今天出了淋巴免疫组化结果:CD3+81.1%,正常,CD8+53.2%偏高(正常值范围18.5%-42.1%),CD4+27.2正常(正常值范围24.5%-48.8%),比2月时做的检查值改善了不少。2 z- S9 i+ T5 O6 z
心肌五酶正常。明天做心超。
% o6 E5 Y3 \! d4 s
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-27 16:07:52 | 显示全部楼层 来自: 哈萨克斯坦
祝福单药泰素帝疗效显著!
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ h( h8 K' k6 P% i% ^3 U- F4 @% ^NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 9 ?% I3 a; C/ P# Y  a
+ Author Affiliations
) Y* g2 n9 f* Y" ?- _6 u1 i2 {5 R. I- N9 P; _
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
0 E/ O' l. i. }4 p$ E2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) s; E  R5 d& @1 e3 S5 K3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' }6 h0 R" \- O8 Y) x4 [  B8 t4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
7 j, i" X# \- Z- Q. v" L1 H5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
3 y1 S: I0 `) [& D6 I* m9 _6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ; J. N) a% r: u$ o# p/ u
7Kinki University School of Medicine, Osaka 589-8511, Japan
) b+ Y7 U4 E7 t8Izumi Municipal Hospital, Osaka 594-0071, Japan 5 D- l2 D. Q/ c4 L$ B6 b3 w7 G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
  G- F0 u+ Y' ?7 z4 [3 O8 bCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp " }7 V4 y0 X4 ^6 c: e( k+ u3 b
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
+ Y9 J4 B. F% D1 N* H( v! }% u6 G. u  M! z9 V' N
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
2 V/ t8 {5 `: p& j- o4 O
. I% b. |( i1 L" T2 sAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 1 q  ~1 X! w0 h4 c: o6 s' s. j

9 ~" f, a# D) z2 n6 z3 qAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
9 k$ G7 A9 a* ~' c) W4 P& N& l/ R
( O( c' {0 S8 ?5 e% s- P# h, gPublished online on: Thursday, December 1, 2011
: y; M( Y6 o" p% W, |. r' J0 V/ w3 g1 `! Q
Doi: 10.3892/ol.2011.507
: }; M6 M2 c# S& Z5 t! G" E/ \. t+ m9 u* H" w; Z* n
Pages: 405-410
' m0 {& H$ O% o! s2 e. Y" M1 V. \+ b4 |' L
Abstract:2 G$ o  w2 t8 v. M7 H* |
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.6 r# ^' g% o( O8 |

8 z% I- m7 C. s' g6 M6 D0 O8 ~
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population" |% h+ R$ R; E: x9 @4 O0 [
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 : K9 A" r8 f, h8 D: m, R
+ Author Affiliations
! Y# ?! G9 w5 f3 ]' h. X1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
2 i6 [$ {1 \1 r" Z0 |& s) ^: a2Department of Thoracic Surgery, Kyoto University, Kyoto / g! i) G8 x- h* P* k
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan   ?% c+ V5 m* N' k
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp - ^$ O: O* l6 G, g. H2 m; p
Received September 3, 2010.
, @4 r7 s  f" v& o$ z3 g% QRevision received November 11, 2010. & v7 r/ V5 I: \8 A( A6 S. P5 D
Accepted November 17, 2010.
- y' r% w0 T% N) E0 p/ YAbstract
0 n" f+ s8 P8 h1 V0 j8 {/ [: e4 tBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
6 h  a7 {5 @  n6 KPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
: M, m" o/ t! z0 iResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
$ ^' z: s( j0 E! B7 Y# v& a7 v/ N0 jConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
+ ?: f; y2 r0 e
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。: q4 T5 h% x7 |8 z# B
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?/ I- Z% [/ E2 f2 f5 x2 k+ N* b) {

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表